vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and TRICO BANCSHARES (TCBK). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $109.4M, roughly 1.7× TRICO BANCSHARES ). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 9.0%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 5.4%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Trico Bancshares is a U.S.-headquartered regional bank holding company operating Tri Counties Bank. It offers a full range of retail and commercial banking services including deposit products, mortgages, small business loans, and wealth management, primarily serving consumers and SMEs in Northern California.
AXSM vs TCBK — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $109.4M |
| Net Profit | — | $33.6M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | 42.6% |
| Net Margin | — | 251.6% |
| Revenue YoY | 57.4% | 9.0% |
| Net Profit YoY | — | 15.8% |
| EPS (diluted) | — | $1.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $109.4M | ||
| Q3 25 | $171.0M | $107.6M | ||
| Q2 25 | $150.0M | $103.6M | ||
| Q1 25 | $121.5M | $98.6M | ||
| Q4 24 | $118.8M | $100.4M | ||
| Q3 24 | $104.8M | $99.1M | ||
| Q2 24 | $87.2M | $97.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $33.6M | ||
| Q3 25 | $-47.2M | $34.0M | ||
| Q2 25 | $-48.0M | $27.5M | ||
| Q1 25 | $-59.4M | $26.4M | ||
| Q4 24 | $-74.9M | $29.0M | ||
| Q3 24 | $-64.6M | $29.1M | ||
| Q2 24 | $-79.3M | $29.0M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 42.6% | ||
| Q3 25 | -27.0% | 43.2% | ||
| Q2 25 | -24.5% | 36.5% | ||
| Q1 25 | -46.9% | 35.8% | ||
| Q4 24 | -61.1% | 38.7% | ||
| Q3 24 | -59.8% | 39.8% | ||
| Q2 24 | -89.5% | 40.0% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | 251.6% | ||
| Q3 25 | -27.6% | 31.6% | ||
| Q2 25 | -32.0% | 26.6% | ||
| Q1 25 | -48.9% | 26.7% | ||
| Q4 24 | -63.1% | 221.4% | ||
| Q3 24 | -61.7% | 29.3% | ||
| Q2 24 | -91.0% | 29.7% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $1.02 | ||
| Q3 25 | $-0.94 | $1.04 | ||
| Q2 25 | $-0.97 | $0.84 | ||
| Q1 25 | $-1.22 | $0.80 | ||
| Q4 24 | $-1.54 | $0.88 | ||
| Q3 24 | $-1.34 | $0.88 | ||
| Q2 24 | $-1.67 | $0.87 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $157.0M |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $1.3B |
| Total Assets | $713.6M | $9.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $157.0M | ||
| Q3 25 | $325.3M | $298.8M | ||
| Q2 25 | $303.0M | $314.3M | ||
| Q1 25 | $300.9M | $308.3M | ||
| Q4 24 | $315.4M | $145.0M | ||
| Q3 24 | $327.3M | $320.1M | ||
| Q2 24 | $315.7M | $206.6M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $1.3B | ||
| Q3 25 | $73.7M | $1.3B | ||
| Q2 25 | $73.1M | $1.3B | ||
| Q1 25 | $53.2M | $1.3B | ||
| Q4 24 | $57.0M | $1.2B | ||
| Q3 24 | $92.9M | $1.2B | ||
| Q2 24 | $102.9M | $1.2B |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $9.8B | ||
| Q3 25 | $669.3M | $9.9B | ||
| Q2 25 | $639.8M | $9.9B | ||
| Q1 25 | $596.7M | $9.8B | ||
| Q4 24 | $568.5M | $9.7B | ||
| Q3 24 | $561.5M | $9.8B | ||
| Q2 24 | $548.2M | $9.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $133.3M |
| Free Cash FlowOCF − Capex | — | $127.9M |
| FCF MarginFCF / Revenue | — | 116.9% |
| Capex IntensityCapex / Revenue | — | 4.9% |
| Cash ConversionOCF / Net Profit | — | 3.96× |
| TTM Free Cash FlowTrailing 4 quarters | — | $222.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $133.3M | ||
| Q3 25 | $1.0M | $45.1M | ||
| Q2 25 | $-32.4M | $29.2M | ||
| Q1 25 | $-43.4M | $24.5M | ||
| Q4 24 | $-26.2M | $109.7M | ||
| Q3 24 | $-18.6M | $28.6M | ||
| Q2 24 | $-30.1M | $31.8M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $127.9M | ||
| Q3 25 | $988.0K | $43.2M | ||
| Q2 25 | $-32.4M | $28.2M | ||
| Q1 25 | $-43.7M | $22.8M | ||
| Q4 24 | $-26.2M | $105.2M | ||
| Q3 24 | $-18.7M | $27.3M | ||
| Q2 24 | $-30.2M | $30.8M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 116.9% | ||
| Q3 25 | 0.6% | 40.2% | ||
| Q2 25 | -21.6% | 27.2% | ||
| Q1 25 | -36.0% | 23.1% | ||
| Q4 24 | -22.1% | 104.8% | ||
| Q3 24 | -17.9% | 27.6% | ||
| Q2 24 | -34.6% | 31.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 4.9% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.3% | 1.7% | ||
| Q4 24 | 0.0% | 4.5% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.1% | 1.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.96× | ||
| Q3 25 | — | 1.33× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 3.78× | ||
| Q3 24 | — | 0.98× | ||
| Q2 24 | — | 1.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
TCBK
Segment breakdown not available.
